Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

Eli Lilly has entered into two strategic collaborations, one with OliX Pharmaceuticals for MASH treatment and another with AdvanCell for cancer therapies2 1.

The deal with OliX Pharmaceuticals is worth up to $630 million and focuses on OLX75016, a Phase I candidate for metabolic-associated steatohepatitis (MASH) and other cardiometabolic diseases3 5.

OLX75016 is an antisense RNAi oligonucleotide developed using OliX's therapeutic RNAi platform, currently in Phase I trials in Australia3 2.

Lilly will make an initial payment to OliX to complete the ongoing Phase I trial of OLX75016, which began in February 20243 8.

The collaboration with AdvanCell aims to advance novel targeted alpha therapies for cancer treatment, leveraging AdvanCell's proprietary Pb-212 production technology1 4.

AdvanCell's agreement with Lilly will combine their Pb-212 targeted alpha therapy expertise with Lilly's drug candidate programs and development capabilities1 8.

These deals diversify Lilly's pipeline in both MASH and cancer treatment areas, complementing their existing efforts with drugs like tirzepatide (Mounjaro and Zepbound)3 8.

The financial terms of the AdvanCell agreement were not disclosed, while the OliX deal includes an upfront payment and potential development and commercial milestones1 3.

Both collaborations aim to accelerate the development and clinical advancement of innovative treatments for hard-to-treat conditions1 8.

These partnerships align with Lilly's recent investments in nucleic acid infrastructure, including a $700 million R&D center in Boston focused on RNA-based and DNA-based medicine3.